Apellis Pharmaceuticals, Inc.

APLS

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

None scheduled

Drug Pipeline

Drug Name	Phase	Indication	Designations
APL-2	Phase 3	Paroxysmal Nocturnal Hemoglobinuria	-
PEGCETACOPLAN (APL-2)	Phase 3	Geographic Atrophy Secondary to Age-related Macular Degeneration	-
Soliris	Phase 3	Paroxysmal Nocturnal Hemoglobinuria	-
Pegcetacoplan	Phase 2	C3G	-
APL-9	Phase 2	COVID	-
APL-3007, pegcetacoplan (APL-2)	Phase 2	Geographic Atrophy Secondary to Age-related Macular Degeneration	-

Catalyst Timeline

0 upcoming, 0 past

No catalysts found.

Regulatory Approvals

APLS News